Japan Slashes Opdivo Price 50% After Prescriptions Surge

Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.

Japanese flag

More from Market Access

More from Pink Sheet